EA3231: A randomized phase III study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with BRAF V600Em.

Authors

• Lova Sun
• Barabra Burtness
• Yael Flamand
• Laila A. Gharzai
• Mei Tang, Greater Baltimore Medical Center (GBMC)
• Nabil F. Saba

Document Type

Article

Publication Title

Journal of Clinical Oncology

DOI

https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS6140

Publication Date

5-27-2026

Recommended Citation

Lova Sun et al. EA3231: A randomized phase III study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with BRAF V600Em.. J Clin Oncol 44, TPS6140-TPS6140(2026).